July 10, 2014
Intezyne Technologies Expands Executive Leadership Team with Two Key Appointments
Jun 19, 2013
Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma
May 15, 2012
Intezyne Adds Chief Business Officer Daniel Devers to Management Team
Intezyne’s IT-235 is a first-in-class targeted gallium-based small molecule administered as oral tablets once daily.
Intezyne, Inc. believes the IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy.